MANTIS Startup to Disrupt Online Advertising Industry With Advanced Online Video Vetting AI Technology
Mantis-ai.com will launch its Artificial Intelligence (AI) tool for the first time, which will be available for advertisers during the #vivatech conference in Paris, May 2018 at startup booth: D17-001, Viva Technology Paris 24-26 May, 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005610/en/
Mantis working process (Graphic: AETOSWire)
Over the past year, SMOs released several official reports surrounding decisions by the largest global advertisers to withdraw ad campaigns from the top four online video publishers, due to failures in online video content vetting and lack of advertiser control over ad placement within relevant content.
Mantis is a video moderation system that uses state-of-the-art AI techniques to identify video content that is relevant for advertisers through a highly efficient content vetting system. The Mantis vetting system detects, classifies and categorizes relevant content based on specified brand attributes and characteristics, ensuring brand safety and efficient spending of online advertising budgets.
Feras Maddah the CEO says, “Advertisers will now have the option of applying pressure on publishers to only place ads in videos that adhere to a brand’s specified ‘safe list.’ This new tool will allow advertisers to conduct online video campaigns more effectively and efficiently, securing brand perception associated with selected content. Within the next 3 months, ongoing trials will conclude and results of the trials will be published with full reports on Mantis’ performance.”
Dr. (PhD) Bernard Ghanem, the Project Director for Mantis says, “Mantis presents an innovative tool for the online advertising world. The system uses sophisticated AI techniques developed in-house to translate brand-safe attributes (similar to those found in an advertising campaign brief) into visual cues that can be very quickly found and recognized in a video. Mantis technology can be used by advertisers in two main ways: (1) to quickly earmark thousands of videos that follow brand specific attributes for ad placement or (2) to assess whether videos with ads already placed in them are coherent with these brand attributes.
Maddah adds, “Mantis will significantly help reduce wastage in advertising spending caused by ad spillovers onto irrelevant or brand-unsafe content and, in turn, improve budget allocation”.
Dr. Ghanem outlines two major benefits of Mantis, “First, Mantis can determine if an activity or cue in a video can be considered brand-safe or unsafe, and consequently, alert the advertiser to whether or not an ad should be placed in that specific video.
Second, Mantis is equipped with an added-value feature where ads can be placed at specific time intervals in a video based on its relevance and favorability to the brand. For example, Mantis can enable advertisers to embed banner ads for sportswear at the exact time a basketball dunk happens in a video across the publisher’s platform. Mantis does this by automatically detecting when that specific activity (basketball dunk) occurs in the video and earmarks it for ad placement.”
FERAS ALMADDAH, +966560690606
Chief Executive Officer
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an
IBC Celebrates Young Talent in the Industry22.7.2019 15:36:00 CEST | Press release
The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 15:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current
Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 13:42:00 CEST | Press release
Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e
Moody’s Analytics Wins Credit Data Provider of the Year at Risk Technology Awards22.7.2019 11:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, has won Credit Data Provider of the Year in the 2019 Risk Technology Awards. It’s one of six categories won, spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005025/en/ The combined strength of Moody’s Analytics offerings earned the Credit Data Provider of the Year award. “We’re honored by this recognition,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Credit data challenges take many forms, and our capabilities are exemplified in a range of award-winning solutions.” Our Data Alliance is among the world’s largest and most comprehensive data consortia. Its global contributors share origination and performance data in C&I, CRE, project finance, asset finance, and other asset classes – and in return receive benchmarking across a host of metrics as well as detailed reports
U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)22.7.2019 11:00:00 CEST | Press release
The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005154/en/ Ronald L. Melnick, PhD, who led the design of the large $30 million NIH/NTP Animal Study, which showed Radio Frequency Radiation emitted by cell phones and wireless devices causes cancer, confirms that the previously held assumption the radiation cannot cause cancer, or other adverse health effects, is wrong. (Photo: Business Wire) There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologica